Cell Therapeutics' phase 1 study of pacritinib shows encouraging anti-tumour ... pharmabiz.com Patients had relapsed following a median of five prior therapies (range 2-15); 44% had failed prior stem cell transplant and 52% were rituximab refractory. Thirty-four patients received daily doses of pacritinib for a 28-day each cycle of doses ranging ... |
